Top Markets
Coin of the day
Vascular Biogenics Ltd. Vascular Biogenics Ltd.

Vascular Biogenics Ltd.

VBLT
株式のランク #33549
Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical... Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical company, dedicated to developing therapeutic solutions for cancer and immune-inflammatory diseases. The company's activities are concentrated in Israel and the United States. Its pipeline is anchored by two core technological platforms: First, a gene-based vascular targeting system that focuses on newly formed blood vessels; and second, an antibody-based monocyte targeting technology that aims to specifically inhibit monocyte migration, particularly for immune-inflammatory applications. VBLT's flagship product candidate, VB-111, a gene-based biologic, is undergoing several clinical trials. It has reached Phase III for the treatment of recurrent, platinum-resistant ovarian cancer. Additionally, it is in Phase II trials for recurrent glioblastoma and colorectal cancer. Moreover, VB-111 has completed Phase II clinical trials for thyroid cancer. The company is also developing VB-601 for a variety of inflammatory indications and VB-611 for different types of solid tumors. Initially incorporated as Medicard Ltd. in 2000, the company rebranded as Vascular Biogenics Ltd. in January 2003. Its main offices are situated in Modi'in, Israel.
株価
$0.155
最終同期: 2023-10-16
時価総額
$7.44M
変化(1日)
-9.36%
変化(1年)
0.00%
IL
取引 Vascular Biogenics Ltd. (VBLT)

カテゴリー

Vascular Biogenics Ltd.(VBLT)の配当利回りの履歴
Vascular Biogenics Ltd.(銘柄コード: VBLT)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Vascular Biogenics Ltd.(VBLT)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)